Patients with colon cancer who still have cancer cells in their blood after surgery may improve their survival odds with ...

Recent research indicates that colon cancer patients with circulating tumor DNA post-surgery may improve their survival likelihood with daily celecoxib use. Celecoxib, a COX-2 inhibitor, significantly ...

A data analysis from a randomized clinical trial for stage 3 colon cancer patients by investigators at Dana-Farber Brigham ...

The recent findings of a huge study may erase some concerns about a pain reliever that has long been saddled with a worrisome reputation: celecoxib (Celebrex). While all nonsteroidal anti-inflammatory ...

A recent analysis from a randomized clinical trial conducted by researchers at the Dana-Farber Brigham Cancer Center ...

An analysis of ctDNA testing for early detection of recurrence showed that test had high sensitivity across multiple sites of ...

Objectives We hypothesised that celecoxib, a COX-2 specific inhibitor, would be as effective as conventional NSAIDs and better than placebo in the treatment of ankle sprain. Methods Two separate ...

Natera has reported the latest data from the Phase III CALGB (Alliance)/SWOG 80702 study, indicating that Signatera, a ...

We evaluated opioid-sparing effects and rehabilitative results after perioperative celecoxib administration for total knee arthroplasty. Methods: This was a prospective, randomized, observer-blind ...

Angioedema is potentially life-threating swelling of integument and mucosa that has multiple potential aetiologies with varying mechanisms. Drug-induced angioedema is often easily correlated with the ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, announced new data from the randomized, ...